Ergoteles’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ergoteles’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,859	Closed	-$624K	–	1689
2023 Q1	$624K	Buy	+6,859	New	+$402K	0.02%	657
2022 Q4	–	Sell	-11,374	Closed	-$286K	–	2052
2022 Q3	$286K	Buy	+11,374	New	+$315K	0.01%	1005
2022 Q1	–	Sell	-45,955	Closed	-$1.21M	–	1732
2021 Q4	$1.21M	Buy	+45,955	New	+$3.56M	0.05%	365
2020 Q4	–	Sell	-28,200	Closed	-$2.75M	–	964
2020 Q3	$2.75M	Buy	+28,200	New	+$3.52M	0.36%	54

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's RETA Position: Q2 2023 in Review

Ergoteles sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 6,859 shares — an estimated $624K sold.

Ergoteles first reported a position in RETA in Q3 2020 and held it in 4 quarters. The position peaked at $2.75M in Q3 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Ergoteles reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 6,859 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $624K.
Ergoteles first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 4 quarters.
Ergoteles's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.75M in Q3 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.